Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?

References

• Panovská A, Doubek M, Brychtová Y, Mayer J. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: recent data from the Czech Leukemia Study Group for Life (CELL). Clin Lymphoma Myeloma Leuk 2010;10(4):297-300
   PubMed Web of Science ®Google Scholar
• Available from: http://seer.cancer.gov/statfacts/html/clyl.html [Last accessed 25 July 2015]
   Google Scholar
• Malcikova J, Smardova J, Rocnova L, et al. Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival and response to DNA damage. Blood 2009;114:5307-14
   PubMed Web of Science ®Google Scholar
• Trbusek M, Smardova J, Malcikova J, et al. Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. J Clin Oncol 2011;29:2703-8
   PubMed Web of Science ®Google Scholar
• Panovská A, Smolej L, Lysák D, et al. The outcome of chronic lymphocytic leukemia patients who relapsed after fludarabine, cyclophosphamide, and rituximab. Eur J Haematol 2013;90:479-85
   PubMed Web of Science ®Google Scholar
• Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008;111:5446-56
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomized, open-label, phase 3 trial. Lancet 2010;376:1164-74
   PubMed Web of Science ®Google Scholar
• Tam CS, O’Brien S, Plunkett W, et al. Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab). Blood 2014;124(20):3059-64
   PubMed Web of Science ®Google Scholar
• Brejcha M, Stoklasová M, Brychtová Y, et al. Clonal evolution in chronic lymphocytic leukemia detected by fluorescence in situ hybridization and conventional cytogenetics after stimulation with CpG oligonucleotides and interleukin-2: a prospective analysis. Leuk Res 2014;38(2):170-5
   PubMed Web of Science ®Google Scholar
• Messina M, Del Giudice I, Khiabanian H, et al. Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. Blood 2014;123(15):2378-88
   PubMed Web of Science ®Google Scholar
• Malcikova J, Stano-Kozubik K, Tichy B, et al. Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia. Leukemia 2015;29(4):877-85
   PubMed Web of Science ®Google Scholar
• Baliakas P, Hadzidimitriou A, Sutton LA, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia 2015;29(2):329-36
   PubMed Web of Science ®Google Scholar
• Smolej L. Therapy of elderly/comorbid patients with chronic lymphocytic leukemia. Curr Pharm Des 2012;18(23):3399-405
   PubMed Web of Science ®Google Scholar
• Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371(3):213-23
   PubMed Web of Science ®Google Scholar
• Furman RR, Sharman JP, Coutre SE. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370(11):997-1007
   PubMed Web of Science ®Google Scholar
• Seymour JF, Davids MS, Pagel JM, et al. Bcl-2 inhibitor ABT-199 (GDC-0199) monotherapy shows anti-tumor activity including complete remissions in high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Blood 2013;122:abstract 872
   Web of Science ®Google Scholar
• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37
   PubMed Web of Science ®Google Scholar
• Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 2003;22:7359-68
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Gregory SA. The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leuk Lymphoma 2010;51:983-94
   PubMed Web of Science ®Google Scholar
• Robak T. Current and emerging monoclonal antibody treatments for chronic lymphocytic leukemia: state of the art. Expert Rev Hematol 2014;7(6):841-57
   PubMed Web of Science ®Google Scholar
• LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood 2008;112(5):1570-80
   PubMed Web of Science ®Google Scholar
• Mack M, Riethmuller G, Kufer P. A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci USA 1995;92:7021-5
   PubMed Web of Science ®Google Scholar
• Loffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 2000;95:2098-103
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gokbuget N, et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011;29(18):2493-8
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler M, Noppeney R, et al. Blinatumomab monotherapy shows efficacy in patients with relapsed diffuse large B cell lymphoma. Blood 2011;abstract 1637
   Google Scholar
• Wong R, Pepper C, Brennan P, et al. Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells. Haematologica 2013;98(12):1930-8
   PubMed Web of Science ®Google Scholar
• Kellner C, Zhukovsky EA, Pötzke A, et al. The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. Leukemia 2013;27(7):1595-8
   PubMed Web of Science ®Google Scholar
• Kosmas C, Stamatopoulos K, Stavroyianni N, et al. Anti-CD20-based therapy of B cell lymphoma: state of the art. Leukemia 2002;16:2004-15
   PubMed Web of Science ®Google Scholar
• Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun 2005;8:140-74
   PubMedGoogle Scholar
• Demidem A, Lam T, Alas S, et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 1997;12:177-86
   PubMed Web of Science ®Google Scholar
• Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-31
   PubMed Web of Science ®Google Scholar
• O’Brien SM, Kantarjian H, Thomas DA, et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19(8):2165-70
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30(26):3209-16
   PubMed Web of Science ®Google Scholar
• Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29(26):3559-66
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28(10):1756-65
   PubMed Web of Science ®Google Scholar
• Smolej L, Doubek M, Panovská A, et al. Rituximab in combination with high-dose dexamethasone for the treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk Res 2012;36(10):1278-82
   PubMed Web of Science ®Google Scholar
• James DF, Werner L, Brown JR, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenterclinical-translational study from the Chronic Lymphocytic Leukemia Research Consortium. J Clin Oncol 2014;32:2067-73
   PubMed Web of Science ®Google Scholar
• Faderl S, Thomas DA, O’Brien S. Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies. Blood 2003;101:3413-15
   PubMed Web of Science ®Google Scholar
• Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-10
   PubMed Web of Science ®Google Scholar
• Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15(10):1090-9
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Buccisano F, et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with Bcell chronic lymphocytic leukemia. Cancer 2008;112:119-28
   PubMed Web of Science ®Google Scholar
• Abrisqueta P, Villamor N, Terol MJ, et al. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia. Blood 2013;122(24):3951-9
   PubMed Web of Science ®Google Scholar
• Greil R, Obrtlikova P, Smolej L, et al. Rituximab Maintenance after Chemoimmunotherapy Induction in 1st and 2nd Line Improves Progression Free Survival: Planned Interim Analysis of the International Randomized AGMT-CLL8/a Mabtenance Trial. Blood 2014;124:abstract 20
   Google Scholar
• Carson KR, Focosi D, Major EO, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009;10(8):816-24
   PubMed Web of Science ®Google Scholar
• Bologna L, Gotti E, Da Roit F, et al. Ofatumumab is more effective than rituximab in B chronic lymphocytic leukemia cells in whole blood and in combination with chemotherapy. J Immunol 2013;190:231-9
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008;111:1094-100
   PubMed Web of Science ®Google Scholar
• Wierda W, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55
   PubMed Web of Science ®Google Scholar
• Moreno C, Montillo M, Panayiotidis P, et al. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the european research initiative on chronic lymphocytic leukemia. Haematologica 2015;100(4):511-16
   PubMed Web of Science ®Google Scholar
• Castro JE, Choi MY, Carvajal T, et al. Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia. Blood Cancer J 2014;4:e258
   Web of Science ®Google Scholar
• Doubek M, Brychtova Y, Panovska A, et al. Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study. Am J Hematol 2015;90(5):417-21
   PubMed Web of Science ®Google Scholar
• Cortelezzi A, Sciumè M Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia 2014;28(3):642-8
   PubMed Web of Science ®Google Scholar
• Costa LJ, Fanning SR, Stephenson JJr, et al. Sequential ofatumumab and lenalidomide for the treatment of relapsed and refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma 2014;1-15. [Epub ahead of print]
   Google Scholar
• Wierda WG, Kipps TJ, Durig J, et al.Chemotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia. Blood 2011;117:6450-8
   PubMed Web of Science ®Google Scholar
• Hillmen P, Robak T, Janssens A, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet 2015;385(9980):1873-83
   PubMed Web of Science ®Google Scholar
• Flinn IW, Harwin W, Macias-Perez IM, et al. A phase II trial of ofatumumab for older patients and patients who refuse fludarabine-based regimens with previously untreated chronic lymphocytic leukemia or small lymphocytic leukemia. Blood 2011;118:abstract 3912
   Web of Science ®Google Scholar
• van Oers MHJ, Kuliczkowski K, Smolej L, et al. Ofatumumab (OFA) maintenance prolongs PFS in relapsed CLL: prolong study interim analysis results. Blood 2014;124:abstract 21
   Web of Science ®Google Scholar
• Owen C, Stewart DA. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther 2012;12:343-51
   PubMed Web of Science ®Google Scholar
• Mossner E, Brunker P, Moser S, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity. Blood 2010;115:4393-402
   PubMed Web of Science ®Google Scholar
• Patz M, Isaeva P, Forcob N, et al. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells. Br J Haematol 2011;152:295-306
   PubMed Web of Science ®Google Scholar
• Cartron G, de Guibert S, Dilhuydy MS, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood 2014;124(14):2196-202
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Morschhauser F, Wegener WA. Veltuzumab (humanized anti-CD20 monoclonal antibody): characterization, current clinical results, and future prospects. Leuk Lymphoma 2010;51:747-55
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, de Vos S, Pohlman BL, et al. Results of a phase 1 study of AME-133v (LY2469298), an Fc-engineered humanized monoclonal anti-CD20 antibody, in FcgRIIIa-genotyped patients with previously treated follicular lymphoma. Clin Cancer Res 2012;18:1395-403
   PubMed Web of Science ®Google Scholar
• Negrea GO, Elstrom R, Allen SL, et al. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin’s lymphoma. Haematologica 2011;96:567-73
   PubMed Web of Science ®Google Scholar
• Awan FT, Hillmen P, Hellmann A, et al. A randomized, open-label, multicenter phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide, and rituximab versus fludarabine, cyclophosphamide, and rituximab alone in subjects with relapsed chronic lymphocytic leukemia. Br J Haematol 2014;167(4):466-77
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P. Anti-CD37 antibodies for chronic lymphocytic leukemia. Exp Opin Biol Ther 2014;14:651-61
   PubMed Web of Science ®Google Scholar
• Byrd JC, Pagel JM, Awan FT, et al. A Phase 1 study evaluating the safety and tolerability of otlertuzumab (TRU-016), an anti-CD37 mono-specific ADAPTIRTM therapeutic protein in chronic lymphocytic leukemia. Blood 2014;123:1302-8
   PubMed Web of Science ®Google Scholar
• Robak T, Hellman A, Kloczko J, et al. Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL). Blood 2013;122:abstract 2860
   Web of Science ®Google Scholar
• Byrd JC, Kipps TJ, Flinn IW, et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab(HCD122) in relapsed chronic lymphocytic leukemia. Leuk Lymphoma 2012;53:2136-42
   PubMed Web of Science ®Google Scholar
• Furman RR, Forero-Torres A, Shustov A, Drachman JG. A phase I study of dacetuzumab (SGN-40, a humanizedanti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:228-35
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-23
   PubMed Web of Science ®Google Scholar
• Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-61
   PubMed Web of Science ®Google Scholar
• Fiegl M, Erdel M, Tinhofer I, et al. Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories. Ann Oncol 2010;21(12):2410-19
   PubMed Web of Science ®Google Scholar
• Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024-31
   PubMed Web of Science ®Google Scholar
• Schnaiter A, Paschka P, Rossi M, et al. NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood 2013;122:1266-70
   PubMed Web of Science ®Google Scholar
• Almasri NM, Duque RE, Iturraspe J, et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocytic leukemia. Am J Hematol 1992;40:259-63
   PubMed Web of Science ®Google Scholar
• Sebejova L, Borsky M, Jaskova Z, et al. Distinct in vitro sensitivity of p53-mutated and ATM-mutated chronic lymphocytic leukemia cells to ofatumumab and rituximab. Exp Hematol 2014;42(10):867-74
   PubMed Web of Science ®Google Scholar
• Pozzo F, Bittolo T, Arruga F, et al. NOTCH1 mutations are associated with low CD20 expression levels in chronic lymphocytic leukemia: evidence for a NOTCH1-mediated epigenetic mechanism. Haematologica 2015;abstract: P578
   Google Scholar
• Stilgenbauer S, Schnaiter A, Paschka P, et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood 2014;123(21):3247-54
   PubMed Web of Science ®Google Scholar
• Del Poeta G, Del Principe MI, Ragusa D, et al. Bendamustine improves clinical outcome in chronic lymphocytic leukemia (CLL) according to different clinical and biological prognostic factors. Blood 2014;124:5668
   Google Scholar
• Beers SA, French RR, Chan HT, et al. Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201
   PubMed Web of Science ®Google Scholar
• Wojciechowski W, Li H, Marshall S, et al. Enhanced Expression of CD20 in Human Tumor B Cells Is Controlled through ERK-Dependent Mechanisms. J Immunol 2005;174:7859-68
   PubMed Web of Science ®Google Scholar
• Tomita A, Hiraga J, Kiyoi H, et al. Epigenetic Regulation of CD20 Protein Expression in a Novel B-Cell Lymphoma Cell Line, RRBL1, Established from a Patient Treated Repeatedly with Rituximab-Containing Chemotherapy. Int J Hematol 2007;86:49-57
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Olejniczak S, Gowda A, et al. Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels. Clin Cancer Res 2008;14:1561-70
   PubMed Web of Science ®Google Scholar
• Hiraga J, Tomita A, Sugimoto T, et al. Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance. Blood 2009;113:4885-93
   PubMed Web of Science ®Google Scholar
• Bil J, Winiarska M, Nowis D, et al. Bortezomib modulates surface CD20 in B-cell malignancies and affects rituximab-mediated complement-dependent cytotoxicity. Blood 2010;115:3745-55
   PubMed Web of Science ®Google Scholar
• Shimizu R, Kikuchi J, Wada T, et al. HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells. Leukemia 2010;24:1760-8
   PubMed Web of Science ®Google Scholar
• Tsai PC, Hernandez-Ilizaliturri FJ, Bangia N, et al. Regulation of CD20 in Rituximab-Resistant Cell Lines and B-cell Non-Hodgkin Lymphoma. Clin Cancer Res 2012;18:1039-50
   PubMed Web of Science ®Google Scholar
• Taylor RP, Lindorfer MA. Fcγ-receptor–mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments. Blood 2015;125(5):762-6
   PubMed Web of Science ®Google Scholar
• Gupta D, Crosby ME, Almasan A, Macklis RM. Regulation of CD20 expression by radiation-induced changes in intracellular redox status. Free Radic Biol Med 2008;44(4):614-23
   PubMed Web of Science ®Google Scholar
• Middelton O, Vosino E, Dobbin E, et al. Komplement deficiencies limit CD20 monoclonal antipody treatment efficacy in CLL. Leukemia 2015;29:107-14
   PubMed Web of Science ®Google Scholar
• Klepfish A, Gilles L, Ioannis K, et al. Enhancing the action of rituximab in chronic lymphocytic leukemia by adding fresh frozen plasma. complement/rituximab interactions & clinical results in refractory CLL. Ann N Y Acad Sci 2009;1173:865-73
   PubMed Web of Science ®Google Scholar
• Beurskens FJ, Lindorfer MA, Farooqui M, et al. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients. J Immunol 2012;188:3532-41
   PubMed Web of Science ®Google Scholar
• Bowles JA, Wang S-Y, Link BK, et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-54
   PubMed Web of Science ®Google Scholar
• Veeramani S, Wang S-Y, Dahle C, et al. Rituximab infusion induces NK activation in lymphoma patients with the high-affinity CD16 polymorphism. Blood 2011;118:3347-9
   PubMed Web of Science ®Google Scholar
• Kohrt HE, Sagiv-Barfi I, Rafiq S, et al. Ibrutinib antagonizes rituximab- dependent NK cell-mediated cytotoxicity. Blood 2014;123(12):1957-60
   PubMed Web of Science ®Google Scholar
• Da Roit F, Engelberts PJ, Taylor RP, et al. Ibrutinib interferes with the cell-mediated anti-tumour activities of therapeutic CD20 antibodies: implications for combination therapy. Haematologica 2015;100(1):77-86
   PubMed Web of Science ®Google Scholar
• Borge M, Bellén Almejún M, Podaza E, et al. Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages. Haematologica 2015;100:e141
   Web of Science ®Google Scholar
• Kamburova EG, Koenen HJ, Borgman KJ, et al. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 2013;13:1503-11
   PubMed Web of Science ®Google Scholar
• Pallasch CP, Leskov I, Braun CJ, et al. Sensitizing Protective Tumor Microenvironments to Antibody-Mediated Therapy. Cell 2014;156(3):590-602
   PubMed Web of Science ®Google Scholar
• Rader C. How to minimalize antibodies. Nature 2015;518:38-9
   PubMed Web of Science ®Google Scholar
• Phase II MOR00208 in combination with lenalidomide for patients with relapsed or refractory CLL, SLL or PLL or older patients with untreated CLL, SLL or PLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02005289
   Google Scholar
• A study of idelalisib and rituximab in elderly patients with untreated CLL or SLL. Available from: https://clinicaltrials.gov/ct2/show/NCT01203930
   Google Scholar
• Lenalidomide plus bendamustine and rituximab for untreated CLL/SLL. Available from: https://clinicaltrials.gov/ct2/show/NCT01400685
   Google Scholar
• Phase I Study of Lenalidomide, Rituximab and Ibrutinib in Relapsed/Refractory CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02200848
   Google Scholar
• Phase II study of bendamustine and rituximab induction chemoimmunotherapy followed by maintenance rituximab (Rituxan®) and Lenalidomide (Revlimid®) in previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01754857
   Google Scholar
• Phase II protocol for CLL with fludarabine and cyclophosphamide with rituximab (FCR) plus lenalidomide. Available from: https://clinicaltrials.gov/ct2/show/NCT01723839
   Google Scholar
• Lirilumab with rituximab for relapsed, refractory or high-risk untreated chronic lymphocytic leukemia (CLL) patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02481297
   Google Scholar
• Study of bendamustine/rituxan induction chemotherapy with revlimid maintenance for relapsed/refractory CLL and SLL. Available from: https://clinicaltrials.gov/ct2/show/NCT00974233
   Google Scholar
• Weekly subcutaneous alemtuzumab and rituximab for relapsed CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT00330252
   Google Scholar
• Efficacy and safety of idelalisib in combination with rituximab in patients with previously untreated chronic lymphocytic leukemia with 17p deletion (Havasu). Available from: https://clinicaltrials.gov/ct2/show/NCT02044822
   Google Scholar
• Cyclophosphamide, alvocidib, and rituximab in treating patients with high risk b-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01076556
   Google Scholar
• Lenalidomide, ibrutinib, and rituximab in treating patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02160015
   Google Scholar
• Ibrutinib and rituximab compared with fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02048813
   Google Scholar
• Fludarabine/rituximab combined with escalating doses of lenalidomide in untreated CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT01703364
   Google Scholar
• Rituximab and bendamustine hydrochloride, rituximab and ibrutinib, or ibrutinib alone in treating older patients with previously untreated chronic lymphocytic leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01886872
   Google Scholar
• Vorinostat, fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00918723
   Google Scholar
• A randomized, double-blind and placebo-controlled study of idelalisib in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01569295
   Google Scholar
• BR in patients with CLL with comorbidities and/or renal dysfunction. Available from: https://clinicaltrials.gov/ct2/show/NCT01832922
   Google Scholar
• A Phase 1b study evaluating the safety and tolerability of ABT-199 in combination with rituximab in subjects with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01682616
   Google Scholar
• Fludarabine phosphate, radiation therapy, and rituximab in treating patients who are undergoing donor stem cell transplant followed by rituximab for high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00104858
   Google Scholar
• R-2cda and prolongation of therapy with rituximab alone in chronic lymphocytic leukaemia and small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01446900
   Google Scholar
• A Study of ibrutinib in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01611090
   Google Scholar
• Rituximab in Pretreated Elderly or Unfit B-CLL Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01576588
   Google Scholar
• Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01269385
   Google Scholar
• Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00602459
   Google Scholar
• FCM-R (Fludarabine, Cyclophosphamide, Mitoxantrone, Rituximab) in Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL) < 70 Years. Available from: https://clinicaltrials.gov/ct2/show/NCT00254410
   Google Scholar
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT00536341
   Google Scholar
• Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01369849
   Google Scholar
• Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab or Obinutuzumab in Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01644253
   Google Scholar
• Expanded Access for Idelalisib in Combination With Rituximab in Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02136511
   Google Scholar
• NOX-A12 in Combination With Bendamustine and Rituximab in Relapsed Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01486797
   Google Scholar
• Fludarabine, Bendamustine, and Rituximab (FBR) in Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01096992
   Google Scholar
• Ibrutinib Versus Ibrutinib + Rituximab (i vs iR) in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL). Avaialble from https://clinicaltrials.gov/ct2/show/NCT02007044
   Google Scholar
• Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02420938
   Google Scholar
• Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23). Available from: https://clinicaltrials.gov/ct2/show/NCT01253460
   Google Scholar
• A Phase II Trial of Alemtuzumab and Rituximab in Patients With Previously Untreated CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT00858117
   Google Scholar
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02158091
   Google Scholar
• Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01744626
   Google Scholar
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic Leukemia (iFCR). Available from: https://clinicaltrials.gov/ct2/show/NCT02251548
   Google Scholar
• Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01446133
   Google Scholar
• Phase 2 Study of the Combination of Bruton’s Tyrosine Kinase Inhibitor PCI-32765 and Rituximab in High-Risk Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01520519
   Google Scholar
• CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b). Available from: https://clinicaltrials.gov/ct2/show/NCT01998880
   Google Scholar
• Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab in Subjects With Previously Untreated Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01980888
   Google Scholar
• Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin’s Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00764517
   Google Scholar
• A Study of GDC-0199 (ABT-199) Plus MabThera/Rituxan (Rituximab) Compared With Bendamustine Plus MabThera/Rituxan (Rituximab) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02005471
   Google Scholar
• Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01871675
   Google Scholar
• Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00816595
   Google Scholar
• Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00602836
   Google Scholar
• Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00940342
   Google Scholar
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT01326702
   Google Scholar
• CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT02168907
   Google Scholar
• Lenalidomide With or Without Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00096044
   Google Scholar
• Rituximab, Alemtuzumab, and GM-CSF As First-Line Therapy in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00562328
   Google Scholar
• Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01013961
   Google Scholar
• Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00711828
   Google Scholar
• Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers. Available from: https://clinicaltrials.gov/ct2/show/NCT00788684
   Google Scholar
• FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia (CLL10). Available from: https://clinicaltrials.gov/ct2/show/NCT00769522
   Google Scholar
• A Study of MabThera (Rituximab) in Combination With Fludarabine and Cyclophosphamide in Patients With Chronic Lymphocytic Leukemia And Favorable Somatic Status. Available from: https://clinicaltrials.gov/ct2/show/NCT01271010
   Google Scholar
• A Study of GDC-0199 (ABT-199) in Combination With Bendamustine And MabThera/Rituxan in Patients With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01671904
   Google Scholar
• A Study of MabThera/Rituxan (Rituximab) in Combination With Fludarabine And Cyclophosphamide as Primary Therapy in Elderly Patients With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01263704
   Google Scholar
• A Study to Compare Mabthera (Rituximab), Fludarabine and Cyclophosphamide to Mabthera and Chlorambucil in Patients With Chronic Lymphocytic Leukemia and Unfavourable Somatic Status. Available from: https://clinicaltrials.gov/ct2/show/NCT01283386
   Google Scholar
• A Study of MabThera (Rituximab) in First Line Treatment of Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00545714
   Google Scholar
• Chemotherapy, Total-Body Irradiation, Rituximab, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00425802
   Google Scholar
• Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT02315118
   Google Scholar
• A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02135133
   Google Scholar
• Lenalidomide and Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01002755
   Google Scholar
• Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01496976
   Google Scholar
• Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01497496
   Google Scholar
• Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT01465334
   Google Scholar
• Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLL (BOMP). Available from: https://clinicaltrials.gov/ct2/show/NCT01612988
   Google Scholar
• Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation. Available from: https://clinicaltrials.gov/ct2/show/NCT01809847
   Google Scholar
• A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01145209
   Google Scholar
• Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01243190
   Google Scholar
• Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01024010
   Google Scholar
• Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01515176
   Google Scholar
• Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01113632
   Google Scholar
• A Trial Looking at Ofatumumab for People With Chronic Lymphocytic Leukaemia Who Cannot Have More Intensive Treatment (RIAltO). Available from: https://clinicaltrials.gov/ct2/show/NCT01678430
   Google Scholar
• An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01532700
   Google Scholar
• Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01361711
   Google Scholar
• Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01352312
   Google Scholar
• Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01659021
   Google Scholar
• Phase II Study of Ofatumumab in Elderly Patients With Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01444716
   Google Scholar
• Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01848145
   Google Scholar
• Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01681563
   Google Scholar
• Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01716208
   Google Scholar
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy (PROLONG). Available from: https://clinicaltrials.gov/ct2/show/NCT01039376
   Google Scholar
• Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01520922
   Google Scholar
• Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia. (CLL0911). Available from: https://clinicaltrials.gov/ct2/show/NCT01762202
   Google Scholar
• Ofatumumab vs Physician’s Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01313689
   Google Scholar
• Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia (COMPLEMENT 1). Available from: https://clinicaltrials.gov/ct2/show/NCT00748189
   Google Scholar
• Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT00824265
   Google Scholar
• A Study of Obinutuzumab (GA101) in Combination With High-Dose Methylprednisolone (HDMP) in Chronic Lymphocytic Leukemia (CLL) Patients (GA101 & HDMP). Available from: https://clinicaltrials.gov/ct2/show/NCT02229422
   Google Scholar
• Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02427451
   Google Scholar
• TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT02100852
   Google Scholar
• Study of Obinutuzumab + Chlorambucil, ACP-196 + Obinutuzumab, and ACP-196 in Subjects With Previously Untreated CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02475681
   Google Scholar
• A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve CLL or SLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02264574
   Google Scholar
• Lenalidomide and Obinutuzumab for Previously Untreated CLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02371590
   Google Scholar
• Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and Maintenance in CLL (CLL2-BCG). Available from: https://clinicaltrials.gov/ct2/show/NCT02445131
   Google Scholar
• Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY). Available from: https://clinicaltrials.gov/ct2/show/NCT02292225
   Google Scholar
• ACP-196 in Combination With Obinutuzumab in Relapsed/Refractory or Untreated CLL/SLL/PLL. Available from: https://clinicaltrials.gov/ct2/show/NCT02296918
   Google Scholar
• CLL11: A Study of Obinutuzumab (RO5072759 [GA101]) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1a). Available from: https://clinicaltrials.gov/ct2/show/NCT01010061
   Google Scholar
• Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01980875
   Google Scholar
• A Safety Study of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01905943
   Google Scholar
• An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01868893
   Google Scholar
• A Study Evaluating the Efficacy of Obinutuzumab and Bendamustine Treatment in Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02071225
   Google Scholar
• A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON). Available from: https://clinicaltrials.gov/ct2/show/NCT01300247
   Google Scholar
• CLLR3: FC + GA101 and B + GA101 in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02320383
   Google Scholar
• Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG). Available from: https://clinicaltrials.gov/ct2/show/NCT02401503
   Google Scholar
• A Study of Obinutuzumab + Bendamustine in Patients With Previously Untreated Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02320487
   Google Scholar
• Sequential Regimen of Bendamustin [B] Followed by GA101 and Ibrutinib [I] in CLL Patients. Available from: https://clinicaltrials.gov/ct2/show/NCT02345863
   Google Scholar
• A Study of GDC-0199 (ABT-199) in Combination With Obinutuzumab in Patients With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01685892
   Google Scholar
• A Study Comparing RO5072759 (GA101) 1000 mg Versus 2000 mg in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GAGE). Available from: https://clinicaltrials.gov/ct2/show/NCT01414205
   Google Scholar
• A Study to Compare the Efficacy and Safety of Obinutuzumab + GDC-0199 Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT02242942
   Google Scholar
• BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT01296932
   Google Scholar
• Safety and Efficacy Study of TRU-016 Plus Bendamustine vs. Bendamustine in Relapsed Chronic Lymphocytic Leukemia. Available from: https://clinicaltrials.gov/ct2/show/NCT01188681
   Google Scholar
• Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine. Available from: https://clinicaltrials.gov/ct2/show/NCT01392079
   Google Scholar
• Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL). Available from: https://clinicaltrials.gov/ct2/show/NCT00951457
   Google Scholar
• Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemia (CLL004). Available from: https://clinicaltrials.gov/ct2/show/NCT01982175
   Google Scholar
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT00040846
   Google Scholar
• Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00935792
   Google Scholar
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT00118352
   Google Scholar
• T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT00683046
   Google Scholar